Skip to main content

Nanomedicine: an integrative approach

Objective

Nanomedicine (NM) is regarded as one of the most promising applications of nanotechnology, as it would allow the development of tailored therapies, with a high level of selectivity and efficacy. Although much research has been performed over the past decades, translation from academia to commercial application remains disappointingly low. Reasons that explain the current moderate success of NM are: (1) promising preclinical results are often poorly predictive for clinical safety and effectiveness, (2) the efficient, scalable and reproducible GMP production of nanocarriers has proven to be challenging and (3) regulatory frameworks are not yet fully equipped to efficiently facilitate the introduction of novel nanomedicines. These obstacles are often encountered since the developmental process from carrier design to clinical assessment is performed by a range of scientists from different backgrounds who have difficulty interacting and communicating with each other to clearly understand the necessary design criteria and the scope and limitations of NM.
NANOMED brings together all the necessary expertise to oversee the entire development trajectory required for NM. This is achieved by the combined effort of 7 beneficiaries from academia and industry and 5 non-academic partner organisations, which are all thoroughly rooted in nanosciences and pharmaceutical sciences. Our objective is to develop scalable and highly controllable design and synthesis methods for the most promising nanomedicine types in a preclinical setting.
NANOMED will train the next generation of NM scientists by offering an extensive joint training programme to 15 incoming ESRs. It focuses on promoting scientific excellence and exploits the specific research and commercial expertise and infrastructure of the NANOMED network as a whole. The exposure to all elements of NM design enables NANOMED to translate expertise from all disciplines to the ESRs, to educate the future leading scientists in the NM field.

Field of science

  • /engineering and technology/nanotechnology
  • /medical and health sciences/medical biotechnology/nanomedicine

Call for proposal

H2020-MSCA-ITN-2015
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

TECHNISCHE UNIVERSITEIT EINDHOVEN
Address
Groene Loper 3
5612 AE Eindhoven
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 652 623,16

Participants (7)

UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 510 748,56
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT GENT
Belgium
EU contribution
€ 751 680
Address
Sint Pietersnieuwstraat 25
9000 Gent
Activity type
Higher or Secondary Education Establishments
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 546 575,76
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 538 290,72
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DE BORDEAUX
France
EU contribution
€ 525 751,20
Address
Place Pey Berland 35
33000 Bordeaux
Activity type
Higher or Secondary Education Establishments
CHEMCONNECTION BV
Netherlands
EU contribution
€ 255 374,28
Address
Molenstraat 110
5342 CC Oss
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STICHTING KATHOLIEKE UNIVERSITEIT

Participation ended

Netherlands
EU contribution
€ 113 499,68
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments

Partners (5)

POLYVATION BV
Netherlands
Address
Kadijk 7D
9747 AT Groningen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SYNTHON BIOPHARMACEUTICALS BV
Netherlands
Address
Microweg 22
6503 GN Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OZ BIOSCIENCES SAS
France
Address
Parc Scientifique Et Technologique De Luminy Case 922 Bat Ccimp
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Retina International
Switzerland
Address

Zurich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enceladus Pharmaceuticals BV
Netherlands
Address
Sint Annastraat 38A
1411PH Naarden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)